PBT2 from the Doherty Institute news site., page-13

Evidence that Prana management did not know anything about the Bohlmann et al paper when they did the Sinclair deal is clear:

1. On 28th of Dec the deal paper does not tell anything of PBT2, only about PBT434 in spite PBT2 is owned by Prana.
2. On 31st of Jan (orphan drug report) again nothing about PBT2 when telling what Prana is, only about PBT434.
3. The answer I got from Prana to my e.mail informing about the Bohlmann paper on the 4th of Feb :."Thank you very much.  I was aware these folks were working on this but did not know they were intending to publish ".

It is clear that Prana was selling to Sinclair PBT434 and it's future but the price did not include anything about PBT2. PBT2 was worthless in these negotiations. Neither buyer or seller understood that PBT2 is very valuable. This is now very difficult issue. General meeting should be in 90 days from the end of Jan and now some 50% of  that time has gone and there is no clear plan IMO. Let us see what happens.